Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17127746 | 0.84 | EGFR (0.68) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL19007030 | 0.80 | EGFR (0.62) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL19006931 | 0.77 | EGFR (0.55) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL4764012 | 0.77 | KMT2A (0.65) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL3324450 | 0.76 | KMT2A (0.59) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL7990884 | 0.75 | OGG1 (0.55) | EGFRKMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL4774229 | 0.74 | L3MBTL1 (0.69) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL3568649 | 0.73 | KMT2A (0.56) | EGFRERBB2KMT2AMEN1L3MBTL1 | |
| SCHEMBL3978340 | 0.72 | EGFR (0.42) | EGFRERBB2 | |
| SCHEMBL14744474 | 0.72 | RORC (0.71) | KMT2AMEN1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015148854-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-10-01 | — | — | WO | disclosed |